Radiation recall pneumonitis in a patient treated by nivolumab for non-small cell lung cancer, no relapse with rechallenge
Keywords:
Radiation Pneumonitis; Immunotherapy; Radiation Recall ReactionsAbstract
Background: Radiation recall pneumonitis is an inflammatory phenomenon occurring in a previously irradiated area of the lungs in response to precipitating agents. The diagnosis is based on clinical features and radiologic abnormalities in the irradiated field and must occur after the administration of an inciting agent. Report: A 58-years-old woman previously treated by left mastectomy and adjuvant radiotherapy for a breast cancer was diagnosed with a right lung adenocarcinoma. Concomitant radio-chemotherapy with irradiation of the upper part of the right hemithorax was performed. Unfortunately, a new metastasis appeared. A new line of treatment with nivolumab was started. Four weeks after the onset of the checkpoint inhibitor, she presented clinical and imaging criteria evoking the diagnosis of RRP induced by nivolumab. A high dose systemic steroid was introduced. As a result, general state, respiratory conditions and imaging features were improved. Conclusions: Some drugs are known to be associated with RRP, mainly traditional chemotherapies. Patients generally improved their condition after a break of the precipitating agent and with steroids. RRP induced by nivolumab has only been described once in a Japanese case report. It constitutes the first report of such a case in Europe.

Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.